The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review
Gastric cancer (GC) is a disease with macromolecular phenotypic heterogeneity and poor prognosis, especially for metastatic GC (mGC). Chemotherapy is the first choice for second-line treatment. However, the benefits of second-line chemotherapy are limited, so there is an urgent need for new treatmen...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.940263/full |
| _version_ | 1818114641489821696 |
|---|---|
| author | Xinwei Wang Yun Zeng Junling Zhang Mengli Huang Bijian Yin |
| author_facet | Xinwei Wang Yun Zeng Junling Zhang Mengli Huang Bijian Yin |
| author_sort | Xinwei Wang |
| collection | DOAJ |
| description | Gastric cancer (GC) is a disease with macromolecular phenotypic heterogeneity and poor prognosis, especially for metastatic GC (mGC). Chemotherapy is the first choice for second-line treatment. However, the benefits of second-line chemotherapy are limited, so there is an urgent need for new treatment regimens to improve patient outcomes. A 65-year-old man with mGC was HER-2 positive. Standard trastuzumab, combined with chemotherapy, was given in the first-line therapy and progression-free survival (PFS) was 8 months. Second-line treatment with pyrotinib in combination with trastuzumab and chemotherapy yielded a PFS of 20 months, in sharp contrast to a median survival of 2.9-6.2 months for a majority of advanced GC patients. This case provides a meaningful reference for the second-line treatment of mGC patients with HER-2 positive. This case also provides valuable information on the response to pyrotinib plus trastuzumab of patients with brain metastases and a better understanding of dual target combination therapy applications in the future. |
| first_indexed | 2024-12-11T03:53:57Z |
| format | Article |
| id | doaj.art-f53df90a0c6b4a41aac7c3e1c07773ee |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-11T03:53:57Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-f53df90a0c6b4a41aac7c3e1c07773ee2022-12-22T01:21:50ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-07-011210.3389/fonc.2022.940263940263The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature ReviewXinwei Wang0Yun Zeng1Junling Zhang2Mengli Huang3Bijian Yin4Department of Medical Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Medical Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, ChinaMedical Department, 3D Medicines Inc., Shanghai, ChinaMedical Department, 3D Medicines Inc., Shanghai, ChinaDepartment of Medical Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, ChinaGastric cancer (GC) is a disease with macromolecular phenotypic heterogeneity and poor prognosis, especially for metastatic GC (mGC). Chemotherapy is the first choice for second-line treatment. However, the benefits of second-line chemotherapy are limited, so there is an urgent need for new treatment regimens to improve patient outcomes. A 65-year-old man with mGC was HER-2 positive. Standard trastuzumab, combined with chemotherapy, was given in the first-line therapy and progression-free survival (PFS) was 8 months. Second-line treatment with pyrotinib in combination with trastuzumab and chemotherapy yielded a PFS of 20 months, in sharp contrast to a median survival of 2.9-6.2 months for a majority of advanced GC patients. This case provides a meaningful reference for the second-line treatment of mGC patients with HER-2 positive. This case also provides valuable information on the response to pyrotinib plus trastuzumab of patients with brain metastases and a better understanding of dual target combination therapy applications in the future.https://www.frontiersin.org/articles/10.3389/fonc.2022.940263/fullHER-2gastric cancerpyrotinibtrastuzumabcase report |
| spellingShingle | Xinwei Wang Yun Zeng Junling Zhang Mengli Huang Bijian Yin The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review Frontiers in Oncology HER-2 gastric cancer pyrotinib trastuzumab case report |
| title | The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review |
| title_full | The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review |
| title_fullStr | The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review |
| title_full_unstemmed | The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review |
| title_short | The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review |
| title_sort | durable effect of pyrotinib plus trastuzumab and chemotherapy in her2 positive gastric cancer with brain metastases a case report and literature review |
| topic | HER-2 gastric cancer pyrotinib trastuzumab case report |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.940263/full |
| work_keys_str_mv | AT xinweiwang thedurableeffectofpyrotinibplustrastuzumabandchemotherapyinher2positivegastriccancerwithbrainmetastasesacasereportandliteraturereview AT yunzeng thedurableeffectofpyrotinibplustrastuzumabandchemotherapyinher2positivegastriccancerwithbrainmetastasesacasereportandliteraturereview AT junlingzhang thedurableeffectofpyrotinibplustrastuzumabandchemotherapyinher2positivegastriccancerwithbrainmetastasesacasereportandliteraturereview AT menglihuang thedurableeffectofpyrotinibplustrastuzumabandchemotherapyinher2positivegastriccancerwithbrainmetastasesacasereportandliteraturereview AT bijianyin thedurableeffectofpyrotinibplustrastuzumabandchemotherapyinher2positivegastriccancerwithbrainmetastasesacasereportandliteraturereview AT xinweiwang durableeffectofpyrotinibplustrastuzumabandchemotherapyinher2positivegastriccancerwithbrainmetastasesacasereportandliteraturereview AT yunzeng durableeffectofpyrotinibplustrastuzumabandchemotherapyinher2positivegastriccancerwithbrainmetastasesacasereportandliteraturereview AT junlingzhang durableeffectofpyrotinibplustrastuzumabandchemotherapyinher2positivegastriccancerwithbrainmetastasesacasereportandliteraturereview AT menglihuang durableeffectofpyrotinibplustrastuzumabandchemotherapyinher2positivegastriccancerwithbrainmetastasesacasereportandliteraturereview AT bijianyin durableeffectofpyrotinibplustrastuzumabandchemotherapyinher2positivegastriccancerwithbrainmetastasesacasereportandliteraturereview |